Transcode Therapeutics annual diluted eps
Diluted EPSBasic EPS
2020
2021
2022
2023
2024
2025
Transcode Therapeutics EPS History: Annual & Quarterly (RNAZ)
Transcode Therapeutics's diluted EPS was -$52.59 for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$52.59 | -$52.59 | $1,284.04 | — |
| 2024 | 2024-12-31 | -$1,336.63 | -$1,336.63 | $94,433.96 | — |
| 2023 | 2023-12-31 | -$95,770.59 | -$95,770.59 | $887,394,862,212.60 | — |
| 2022 | 2022-12-31 | -$887,394,957,983.19 | -$887,394,957,983.19 | -$354,957,983,193.28 | — |
| 2021 | 2021-12-31 | -$532,436,974,789.92 | -$532,436,974,789.92 | -$197,198,879,551.82 | — |
| 2020 | 2020-12-31 | -$335,238,095,238.10 | -$335,238,095,238.10 | — | — |
Transcode Therapeutics quarterly diluted eps
Diluted EPSBasic EPS
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$7.17 | -$7.17 | -$2.04 | — |
| Q1 2026 | 2026-03-31 | -$21.28 | -$21.28 | $48.88 | — |
| Q3 2025 | 2025-09-30 | -$5.82 | -$5.82 | $140.24 | — |
| Q2 2025 | 2025-06-30 | -$5.13 | -$5.13 | $675.10 | — |
| Q1 2025 | 2025-03-31 | -$70.16 | -$70.16 | $527.88 | — |
| Q3 2024 | 2024-09-30 | -$146.06 | -$146.06 | $49,751,487.93 | — |
| Q2 2024 | 2024-06-30 | -$680.23 | -$680.23 | $146,234,613.89 | — |
| Q1 2024 | 2024-03-31 | -$598.04 | -$598.04 | $266,084,369.28 | — |
| Q3 2023 | 2023-09-30 | -$49,751,633.99 | -$49,751,633.99 | $10,812,619,981.33 | — |
| Q2 2023 | 2023-06-30 | -$146,235,294.12 | -$146,235,294.12 | $11,685,697,478.99 | — |
| Q1 2023 | 2023-03-31 | -$266,084,967.32 | -$266,084,967.32 | $177,212,906,629.32 | — |
| Q3 2022 | 2022-09-30 | -$10,862,371,615.31 | -$10,862,371,615.31 | $120,603,548,085.90 | — |
| Q2 2022 | 2022-06-30 | -$11,831,932,773.11 | -$11,831,932,773.11 | -$347,070,028,011.20 | — |
| Q1 2022 | 2022-03-31 | -$177,478,991,596.64 | -$177,478,991,596.64 | $460,130,718,954.25 | — |
| Q3 2021 | 2021-09-30 | -$131,465,919,701.21 | -$131,465,919,701.21 | $65,732,959,850.61 | — |
| Q2 2021 | 2021-06-30 | $335,238,095,238.10 | $394,397,759,103.64 | $354,957,983,193.28 | — |
| Q1 2021 | 2021-03-31 | -$637,609,710,550.89 | -$637,609,710,550.89 | — | — |
| Q3 2020 | 2020-09-30 | -$197,198,879,551.82 | -$197,198,879,551.82 | — | — |
| Q2 2020 | 2020-06-30 | -$19,719,887,955.18 | -$19,719,887,955.18 | — | — |
Transcode Therapeutics diluted eps trends
Over the last five fiscal years, Transcode Therapeutics's diluted eps increased from -$335,238,095,238.10 to -$52.59, a change of $335,238,095,185.51. The latest reported quarter, Q2 2026, shows -$7.17.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗